JONATHAN MELIUS: Open Payments
NPI 1194034157 · TRENTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,560 in 121 payments from 14 companies in 2025. Trend: 2023 $1,413 · 2024 $1,416 · 2025 $2,560
Food & beverage: $2,449Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $526 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $361 |
| Janssen Pharmaceuticals, Inc | 16 | $350 |
| Teva Pharmaceuticals USA, Inc. | 13 | $323 |
| Otsuka America Pharmaceutical, Inc. | 7 | $174 |
| Neurocrine BioSciences, Inc. | 9 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $129 |
| Axsome Therapeutics, Inc. | 6 | $126 |
| Lundbeck LLC | 5 | $119 |
| Supernus Pharmaceuticals, Inc. | 4 | $79 |
Products named: VRAYLAR, CAPLYTA, REXULTI, SPRAVATO, INGREZZA, TRINTELLIX, Auvelity, INVEGA SUSTENNA.
Industry payments across NJ — which companies pay providers there.
